DDInter530 DDInter1763
The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Dextrothyroxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) downregulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Dextrothyroxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) downregulates {v} (Gene) ATP6V1D
ATP6V1D {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Dextrothyroxine {u} (Compound) downregulates {v} (Gene) HSPD1
HSPD1 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dextrothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dextrothyroxine (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Temsirolimus (Compound)
Dextrothyroxine (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Temsirolimus (Compound)
Dextrothyroxine (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Temsirolimus (Compound)
Dextrothyroxine (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Temsirolimus (Compound)
Dextrothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Dextrothyroxine (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dextrothyroxine (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dextrothyroxine (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Temsirolimus (Compound)
Dextrothyroxine (Compound) downregulates HSPD1 (Gene) and HSPD1 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)